Human osteoclast-derived cathepsin
Patent 5501969 Issued on March 26, 1996. Estimated Expiration Date: 
March 8, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 8, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Inventors
AssigneeApplicationNo. 208007 filed on 03/08/1994US Classes:435/252.33, Escherichia (e.g., E. coli, etc.)435/252.3, Transformants (e.g., recombinant DNA or vector or foreign or exogenous gene containing, fused bacteria, etc.)435/254.11, Transformants435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)536/23.2, Encodes an enzyme536/24.3Probes for detection of specific nucleotide sequences or primers for the synthesis of DNA or RNAExaminersPrimary: Wax, Robert A.Assistant: Grimes, Eric Attorney, Agent or FirmInternational ClassesC12N 015/57C12N 015/63 C12N 001/21 C12N 005/10 AbstractDisclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Other References
|
| ||||||||||||||
